introduction
Androgen receptor (AR) is a member of the nuclear receptor (NR) super family that acts as a ligand-dependent transcriptional regulator. Upon stimulation with androgen, AR undergoes an androgen-specific intramolecular interaction between the activation function 1 (AF1) in the N-terminal domain (NTD) and the activation function 2 (AF2) in the ligand binding domain (LBD). 1, 2 An androgen-induced intramolecular interaction between the AF1 and AF2 regions of AR is mediated by two LXXLL-like peptide sequences in the AR NTD, i.e., 23 FQNLF 27 and 433 WHTLF 437 (L = leucine (hydrophobic), F = phenylalanine (hydrophobic), X = any amino acid). A previous sequence analysis of AR NTD revealed five predicted amphipathic α-helices that resemble LXXLL core sequences at residues 21 -34, 177 -201, 351 -359, 395 -405, and 432 -434. [3] [4] [5] The potential implication of their interactions with monomeric AR should be explored. However, AR LBD-peptide interactions are generally weak, and thus difficult to be estimated with conventional methodologies.
It is generally known that AR consists of a well-conserved DNA binding domain (DBD) and LBD in addition to the variable N-terminal domain. 1, 6, 7 It is still unclear how AR can precisely discriminate the chemically resembled steroids and express the male phenotypes. We anticipated that (i) the ligand selectivity of AR is deeply related with the variable AR NTD, in addition to the highly conserved AR LBD, and (ii) unknown functional peptides may exist in AR NTD and be responsible for precise inter-or intramolecular communications of AR. Although this anticipation is plausible, it has been a tough mission to determine the weak association of AR LBD with a functional peptide inside AR NTD in a physiological circumstance of living cells. We previously introduced an integrated-molecule-format (IMF) bioluminescent indicator for determining ligand-activated protein-protein (peptide) interactions. [8] [9] [10] This IMF probe provides an advanced methodology for determining weak protein-protein (peptide) interactions of interest. Here, the methodological advantage of IMF probes was demonstrated through an exploration of the binding chemistry between AR LBD and the functional peptides in AR NTD. We also describe improved sensorial properties of the probes carrying the N-terminal peptide of AR to androgens. First, we constructed four different plasmids comprising oligomers encoding the peptides, as shown in Fig. 1(A) , e.g., the leucine-rich region ( 50 PGASLLLLQQ 59 ) and the proline-rich region ( 373 GPPPPPPPPHP 382 ) inside AR NTD. The functional leucine-or proline-rich peptides were genetically fused with AR LBD, both ends of which were then sandwiched between the N-and C-terminal fragments of split-firefly luciferase (FLuc). On the basis of the AR LBD-peptide binding, the dissected The present study demonstrates a single-molecular bioluminescent probe carrying functional peptides in the N-terminal domain of the androgen receptor (AR NTD) with an improved sensorial property to androgens. The N-terminal peptides in AR were genetically fused to the ligand binding domain of AR (AR LBD) with a flexible linker, and then sandwiched between the N-and C-terminal fragments of split-firefly luciferase (FLuc) dissected at D415. We found that the proline-rich region in AR NTD efficiently interacts with AR LBD and exerts (i) an enhanced signal-to-background ratio and (ii) discrimination between agonists and antagonists with (iii) a 100-times improved sensitivity to androgens, upon comparison with previous references. A deletion mutation to the proline-rich region in AR revealed that this region is critical for the transcriptional activities. The quantum yields of these single-chain probes were estimated to be 37.8 ± 0.6%. This monomeric AR LBD-peptide binding is necessary, and sufficient for discriminating an agonist and an antagonist, where the dimerization of AR LBD is not involved. The present study guides a fundamental methodology on how to discriminate weak protein-peptide binding, and provides a new insight into the contribution of functional peptides in AR NTD to the initial activation of monomeric AR. With the custom-made probes, we demonstrated the ligand-activated binding chemistries between AR LBD and peptides, and an application to androgen recognition. Among the peptides, the proline-rich peptide in AR NTD interacts with AR LBD and exerts an excellent signal-to-background ratio with a 100-times-improved detection limit. According to a reporter gene assay, the proline-rich region in AR NTD is found to be of critical importance in the initial AR actions. We conclude that this initial, monomeric AR LBD-peptide binding is necessary and sufficient for discriminating agonists from antagonists, where the dimerization of AR LBD is not involved.
experimental

Plasmid construction
The present plasmids (pLeu-rich, pPro-rich, pPro-mut, and pAR-dim) were constructed by subcloning each specific oligomer encoding peptide into pcDNA 3.1(+) vector backbone (Invitrogen) (Fig. 1(A) ). 8 The specific steps were as follows. The cDNAs of N-terminal (FLuc-N; 1 -415 AA) and C-terminal (FLuc-C; 416 -510 AA) domains of split-firefly luciferase (FLuc; Promega) were amplified to introduce each unique restriction site at both ends of the domains using adequate primers and a template plasmid carrying cDNA of full-length FLuc. The cDNA encoding human AR LBD (672 -910 AA) was modified by polymerase chain reaction (PCR) to introduce unique KpnI and NotI sites, or NotI and BamHI sites, at the respective N-and C-terminal ends of the domains. cDNA oligomers encoding specific leucine-and proline-rich peptides, 50 PGASLLLLQQ 59 and 373 GPPPPPPPPHP 382 , were made-to-order by Exigen (Tokyo, Japan). The oligomers were designed to comprise NotI and BamHI sites at the respective N-and C-terminal ends. The cDNA fragments were ligated and the consequent chimeras were subcloned into pcDNA 3.1(+) vector backbone (Invitrogen) digested by the corresponding restriction enzymes. The constructed plasmids were sequenced to ensure fidelity with a BigDye Terminator Cycle Sequencing kit and a genetic analyzer ABI Prism310 (Applied Biosystems). The plasmids were named pLeu-rich, pPro-rich, and pPro-mut, respectively, according to the cDNAs encoding the functional peptides.
Deletion mutants of AR were made as follows: the proline-rich region was deleted by PCR to replace the oritinal C-terminal fragment near CpoI with a proline-deficient fragment in AR. This manipulation deletes the region "GPPPPPPHP" in AR. On the other hand, a leucine-deficient AR variant was made by replacing the original N-terminal fragment near PstI with a leucine region-deficient fragment. This manipulation removed the region "PGASLLLL" in AR (see Fig. S1 for the map in Supporting Information). 
A reporter-gene assay for examining the significance of the proline-and leucine-rich regions in AR
The significance of the proline-and leucine-rich regions in the expression efficiency of AR was determined with a reporter-gene assay ( Fig. 1(B) ).
The reporter vector comprising the AR-recognition element (ARE) and cDNA encoding FLuc as a reporter was purchased from Panomics (pTransLucent). African green monkey kidney fibroblast-derived COS-7 cells raised in a 24-well plate were cotransfected with (i) the reporter vector (ii) a vector encoding Renilla luciferase as an internal reference (0.2 μg per each well), (iii) a plasmid carrying cDNA encoding full-length AR (positive control), leucine-deficient AR, or proline-deficient AR. Six hours after transfection, the cells were stimulated with 10 -6 mol L -1 5α-dihydrotestosterone (DHT). The resulting reporter expression was determined with a Dual-luciferase assay kit (Promega). The results are shown in Fig. 1(B) .
The expression levels of AR variants were estimated by a western blot analysis ( Fig. 1(C) ). The experiment procedure was followed according to a previous reference. 8 In brief, the AR variants were recognized with mouse anti-AR antibody or mouse anti-β-actin antibody, blotted with horseradish peroxidase (HRP)-conjugated secondary antibody, and finally visualized by chemiluminescence (GE Healthcare).
Androgen sensitivities of HeLa cells carrying pPro-rich or pLeu-rich
Contributions of androgen agonists and antagonists to the association between AR LBD and a specific peptide were evaluated ( Fig. 2(A) ). Human cervical carcinoma-derived HeLa cells were cultured in 12-well plates in Dulbecco's modified eagle's medium (DMEM; Sigma) supplemented with 10% steroid-free fetal bovine serum (FBS) and 1% penicillinstreptomycin (P/S) at 37 C in a 5% CO2 incubator (Sanyo). The cells in the 12-well plates were transfected with pPro-rich or pLeu-rich using a transfection reagent (TransIT-LT1 (Mirus)) and extensively incubated for 16 h. The HeLa cells in each well were prestimulated with a vehicle (0.1% DMSO) or 5 × 10 -5 mol L -1 antagonist (final conc.) for 5 min. All of the cells except for the positive control were additionally stimulated with a 10 -6 mol L -1 DHT for 20 min. The examined antagonists were flutamide and cyproterone acetate (CPA).
The luminescence intensities of each well were then determined using a substrate kit (Bright-Glo; Promega) and a luminometer (Minilumat LB9506; Berthold).
The obtained firefly luminescence intensities were represented as "relative luminescence unit (RLU) ratio (+/-)", i.e., the ratio of RLU (+)/ RLU (-), where RLU (+) and RLU (-) mean the luminescence intensity from a l-μg protein of cell lysate after HeLa cells were incubated with or without a ligand, respectively.
Comparison of the androgen sensitivity of various cell lines carrying pPro-rich
The androgen sensitivities of various mammalian cell lines was examined to demonstrate the influence of the cell context on the AR LBD-peptide binding (Fig. 2(B) ). Four kinds of mammalian cell lines were raised in a 12-well plate to a 90% confluent. They were (i) Chinese hamster ovary-derived CHO cells, (ii) human cervical carcinoma-derived HeLa cells, (iii) African green monkey kidney fibroblast-derived COS-7 cells, and (iv) human breast cancer-derived MCF-7 cells. Each cell line was transiently transfected with pPro-rich using a The time-course of the bioluminescence intensities from the HeLa cells carrying pPro-rich in response to DHT was monitored to determine the ligand sensitivity based on AR LBD peptide binding (Fig. 2(B) 
Reversibility of the AR LBD-proline-rich peptide binding in response to DHT
The reversibility of AR LBD-proline-rich peptide binding was evaluated through a repeated treatment and the withdrawal of DHT (Fig. 3) . HeLa cells cultured in a 24-well plate were transfected with pPro-rich using the transfection reagent (Mirus). At 16 h after extensive incubation, all of the cells, but a negative control on the plate wells, were stimulated with 10 -5 mol L -1 DHT for 20 min. The medium on the wells was then replaced with a fresh DMEM supplemented with 10% FBS and 1% P/S. At 20, 40, 60, and 120 min after the medium change, the luminescence intensities were determined using the Bright-Glo substrate kit. The remaining cells in the 24-well plate were stimulated once again with 10 -5 mol L -1 DHT for 20 min. The medium in the plate wells was replaced again with a fresh DMEM supplemented with 10% FBS and 1% P/S for removing DHT. At 20, 40, 60, and 120 min after the second medium change, the recovered FLuc activities were determined using the Bright-Glo substrate kit.
Quantum yield of Pro-rich probe
For measurements of the quantum yield (QY), COS-7 cells cultured in a 6-well plate (1 × 10 5 cells per well) were transfected with pPro-rich, pPro-mut, or pLeu-rich and incubated 24 h for overexpression. The cells were stimulated with 0.1% DMSO or 10 -5 mol L -1 DHT for 20 min, lysed, and finally transferred into a 96-well glass-bottom plate (black-frame), which was loaded in an automatic microplate reader (Mithras LB 940; Berthold). Immediately after automatic injection of D-luciferin (0.157 pmol in 10 μL of PBS, pH 7.4) into each well, the total light output was integrated for 10 min at 22.5 C.
Results and Discussion
Selection of functional peptides in AR NTD that bind AR LBD
Upon stimulation with a ligand, the AR LBD forms a hydrophobic binding site for interacting with the LXXLL motifs of coactivators. 6, 7, 11 Thus, potential peptides binding AR LBD should have a hydrophobic property. Practically, all of the motifs known to bind AR LBD, e.g., LXXLL, FXXLF, and WXXLF, consist of hydrophobic amino acids, leucine (L) or phenylalanine (F), as a key component. Therefore, we also anticipated that the hydrophobicity of peptides is a critical character for binding AR LBD. In the long amino acid sequences of AR NTD, the proline-rich region from G373 to P382 ( 373 GPPPPPPPPHP 382 ) is a representative hydrophobic region in the NTD according to a hydrophobicity search (SOSUI).
In addition, the sequence from P50 to Q59 ( 50 PGASLLLLQQ 59 ) comprises a consecutive leucine-rich sequence that resembles the conserved LXXLL motif of AR coactivators for binding AR LBD. The proline-rich region of AR is known to interact with protein kinase Src for cell growth, differentiation, and cell survival, whereas the physiological importance of the leucine-rich region in AR NTD is still veiled. We previously introduced an integrated-molecule-format (IMF) bioluminescent probe for determining ligand-stimulated protein-protein interactions, i.e., an intramolecular protein complementation. 8 For signal development, an intramolecular complementation system between N-and C-terminal fragments of split-FLuc that yields a significant recovery of the enzymatic activity was fabricated inside a single-chain molecule (Fig. 1(A) ). The N-and C-terminal fragments of split-FLuc used for this study were generated by dissecting FLuc between 415 and 416 AA. This dissection point corresponds with one of the splitting points examined by Paulmurugan et al., 12 though this dissection point, D415, was not considered to be attractive compared to the other dissection sites.
Based on the upper consideration, a series of IMF probes carrying the proline-or leucine-rich peptides was synthesized and utilized in a subsequent exploration of androgenicity of the ligands.
Significance of proline-and leucine-rich region in AR upon AR sensing ligands
To examine the functional significance of the proline-and leucine-rich region in human AR regarding ligand sensitivity, we conducted a reporter-gene assay with the deletion variants of AR ( Fig. 1(B) ).
The stimulation of COS-7 cells carrying proline-or leucine-deficient variants of AR with 10 -6 mol L -1 DHT exerts various levels of the reporter protein (FLuc) expression. The cells carrying both intact AR and leucine-deficient AR exhibited strong transcriptional activities, whereas those carrying proline region-deficient AR showed remarkably decreased expression efficiency. The present results in Fig. 1(B) suggest that the proline-rich region exerts a pivotal role in the ligand sensitivity of AR and the subsequent transcriptional efficiency.
The expression levels of the three types of AR variants were parallelly examined with a western blot analysis. No significant variance in the expression levels of the deletion-mutated ARs was observed (Fig. 1(C) ).
Effects of androgen antagonists on the AR LBD-peptide binding
Screening for a safe androgen antagonist is directly related to the development of a prostate cancer drug. The inhibitory effects of androgen antagonists on AR LBD-peptide binding show whether the binding is an antagonist-controlled molecular event (Fig. 2(A) ). Inhibitory effects of the androgen antagonists, flutamide and CPA, on the DHT-induced AR LBD-peptide binding were observed with probes carrying the proline-or leucine-rich peptides. Both of the probes from pPro-or pLeu-rich commonly reported that CPA is a highly potent antagonist to the binding.
Flutamide nearly quenched the luminescence from the cells carrying pLeu-rich, but not from the cells carrying pPro-rich. This result in Fig. 2(A) shows that flutamide selectively inhibits the AR LBD-leucine-rich peptide binding, but not the AR LBD-proline-rich peptide binding. This selective inhibition was not observed with CPA. It suggests that flutamide induces a distinctive conformational change of AR LBD for peptide binding, different from other antagonists.
These results show that (i) the proline-rich regions in AR NTD are a sensitive index for nongenomic activities of the ligands, considering that the proline-rich peptide in AR interacts with Src in the nongenomic pathway; 13 also, (ii) the proline-rich region in AR NTD has two competitive binding options, i.e., interacting with AR LBD (intramolecular, shown here) or with Src (intermolecular, previously known); and (iii) the biased inhibitory effects show that flutamide-and CPA-bound AR LBDs interact with distinct regions (e.g., proline-or leucine-rich) of the AR NTD, which resulted in different binding constants.
Androgen sensitivity of various mammalian cells carrying pPro-rich
The androgen sensitivity of various mammalian cell lines carrying pPro-rich was compared in order to examine the influence of the cell context on AR LBD-proline-rich peptide binding (Fig. 2(B) ). The detection limits of the proline-rich probe in MCF-7 and CHO cells were approximately 100-times improved compared to the previous references (Fig. 2(B) ). 8 The signal-to-background ratios of the CHO and MCF-7 cells were higher than those of the HeLa and COS-7 cells. The ligand sensitivity variances according to cell lines are interpreted as follows: (i) The expression level of the probe differs according to the host cell lines, although pPro-rich was equally transfected.
(ii) The present interaction model between AR LBD and proline-rich peptide is generally applicable in various physiological contexts of cell lines upon determining the androgenicity of ligands.
Here, we supposed that ligand-activated AR LBDs have a potential to make dimers through an intermolecular association, as evaluated previously. 14 It was examined with a specially designed probe vector, named pAR-dim (Fig. 2(B) ). The probe was designed to contain two tandem AR LBDs, which were directly linked without a flexible linker. pAR-dim induced no considerable increase in the luminescence intensities in response to varying concentrations of DHT ranging from 10 -10 to 10 -5 mol L -1 . This dramatic difference between pAR-dim and pPro-rich suggests that the luminescence development is contributed by the intramolecular AR LBD-peptide binding, not by the intermolecular AR LBD-AR LBD interactions.
Kinetics of the association of AR LBD with proline-rich or leucine-rich peptides
The kinetics of the association of AR LBD with the prolineor leucine-rich peptide was monitored for exploring the detailed binding property (Fig. 2(B) It is interesting to consider the driving force of the peptide-AR LBD binding. Previous studies suggest that two main driving forces exist in the ligand-activated AR LBD-functional peptide binding: one is the hydrogen bond 15 and the other is the hydrophobic interaction. 6, 7, 11 Considering that well-known LXXLL or FQNLF motifs contain efficient side chains for producing hydrogen bonds with AR LBD, 6 the preference to hydrogen bonds and hydrophobicity might also be a decisive reason in the present binding model.
Reproducible sensitivity of the probe from pPro-rich to DHT
We examined whether AR LBD-proline-rich peptide binding is reversible in response to ligands (Fig. 3) . The initial addition of 10 -5 mol L -1 DHT increased the luminescence intensities from HeLa cells carrying pPro-rich to be 22-times larger than that of the vehicle (0.1% DMSO). After a medium change with fresh DHT-free DMEM, the variation of the luminescence intensities was monitored. The luminescence intensities sharply decreased 20 min after the medium change, and returned to the background intensity in 1 h. An additional stimulation with 10 -5 mol L -1 DHT increased the luminescence intensities again up to 18 times, compared to that of the vehicle. The recovered luminescence intensities were about 80% of the initial intensities. By the second medium change with a fresh one, the luminescence intensities decreased again, and finally reached the background in 1 h. The present study represents that the probe expressed from pPro-rich preserves sensitivity for DHT. QYs of the present probes carrying proline-rich or leucine-rich peptide were found to be almost the same after the addition of DHT (Table 1) .
QY of FLuc differs according to the references. Seliger et al. previously reported to be ca. 84% at 25 C and pH 7.4, 16 whereas Ando et al. represented it to be ca. 41%. 17 On the other hand, our calculation showed that QY of the Pro-rich probe carrying the fragmented FLuc is 38%.
In the present study, the splitting of FLuc at D415 dissects the active site pocket into two fragments, from knowledge that the active site pocket ranges from H245 to K529. 18 The fragmented active site pocket may influence the slight decrease of the QYs.
Conclusion
Taken together, we first investigated the potential functional peptides inside the AR NTD for recruiting AR LBD using a series of IMF probes. We found that the proline-rich peptide in AR NTD is an excellent functional peptide upon determination of the androgenicity of the ligands, considering the enhanced detection limits and the S/B ratios. The flutamide selectively inhibited the AR LBD-leucine-rich peptide association, not the AR LBD-proline-rich peptide binding, suggesting that the conformations of AR LBD differ according to the ligands. QYs of the IMF probes almost corresponded with those of Ohmiya et al., but less than those of Seliger et al. All of the collected results suggest that proline-rich peptides interact with AR LBD as an initial conformation change that is sufficient to discriminate agonists and antagonists, and thus AR may direct ligand-activated signaling pathways with such an intramolecular communication. Weak protein-peptide interactions are generally difficult to be estimated with conventional methods. The present study also demonstrates a fundamental methodology for discriminating weak protein-peptide binding, and a new insight into the binding chemistry between functional peptides and AR LBD as an initial activation setp of monomeric AR. Figure S1 , mapping of amino acid sequences in the N-terminal domain of AR that were used for the present study. The amino acid sequences incorporated in the plasmids, pLeu-rich and pPro-rich were 50 PGASLLLLQQ 59 and 373 GPPPPPPPPHP 382 , respectively. This material is available free of charge on the Web at http://www.jsac.or.jp/analsci/. 
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